Assessment of telomerase activity in cells from urine samples for bladder cancer detection

2017 ◽  
Vol 16 (10) ◽  
pp. e2772
Author(s):  
N. Potoldykova ◽  
K. Polyakovsky ◽  
A. Vinarov ◽  
P. Glybochko ◽  
A. Glukhov ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Detection ◽  
Telomerase Activity ◽  
Urine Samples ◽  
In Cells

scholarly journals Electronic Nose for Bladder Cancer Detection

2021 ◽  
Vol 5 (1) ◽  
pp. 22
Author(s):  
Heena Tyagi ◽  
Emma Daulton ◽  
Ayman S. Bannaga ◽  
Ramesh P. Arasaradnam ◽  
James A. Covington
Keyword(s):  
Bladder Cancer ◽  
Logistic Regression ◽  
Random Forest ◽  
Sensitivity And Specificity ◽  
Cancer Detection ◽  
Electronic Nose ◽  
Random Forest Classifier ◽  
Urine Samples ◽  
Sparse Logistic Regression ◽  
High Separation

This study outlines the use of an electronic nose as a method for the detection of VOCs as biomarkers of bladder cancer. Here, an AlphaMOS FOX 4000 electronic nose was used for the analysis of urine samples from 15 bladder cancer and 41 non-cancerous patients. The FOX 4000 consists of 18 MOS sensors that were used to differentiate the two groups. The results obtained were analysed using s MultiSens Analyzer and RStudio. The results showed a high separation with sensitivity and specificity of 0.93 and 0.88, respectively, using a Sparse Logistic Regression and 0.93 and 0.76 using a Random Forest classifier. We conclude that the electronic nose shows potential for discriminating bladder cancer from non-cancer subjects using urine samples.

Label free Impedimetric Immunosensor for effective bladder Cancer detection in clinical urine samples

2020 ◽  
Vol 22 (3) ◽  
Author(s):  
Muhammad Omar Shaikh ◽  
Ting-Chi Huang ◽  
Ting-Feng Wu ◽  
Cheng-Hsin Chuang
Keyword(s):  
Bladder Cancer ◽  
Cancer Detection ◽  
Urine Samples ◽  
Label Free ◽  
Impedimetric Immunosensor

Developing a new urine cell flow cytometry analysis of PD-L1 expression and DNA content for diagnosis of bladder cancer.

2019 ◽  
Vol 37 (8_suppl) ◽  
pp. 60-60
Author(s):  
Shaheen Riadh Alanee ◽  
Mustafa Deebajah ◽  
Pin-I Chen ◽  
Alice (Xiaoyang) Wang ◽  
Bruce Kendrick Patterson
Keyword(s):  
Flow Cytometry ◽  
Bladder Cancer ◽  
Epithelial Cells ◽  
Cancer Patients ◽  
Dna Content ◽  
The United States ◽  
Urine Samples ◽  
Normal Donor ◽  
Urine Testing ◽  
In Cells

60 Background: Bladder cancer is the fifth most common cancer in the United States. PD-1/PD-L1, a pathway used by cancer cells to evade immune response, correlates with bladder cancer severity and has emerged as a target in bladder cancer treatment. Chromosomal instability is also a prominent feature associated with the development of bladder cancer. A method for unbiased analysis of PD-L1 expression and DNA content in cells from urine samples promises to be a new test for diagnosis of bladder cancer. Methods: To evaluate the PD-L1 expression and DNA content, we developed a 4-color flow assay. Cells in voided urine samples were pelleted, fixed in incellMAX (IncellDx Inc.) and stained with antibodies against pan-cytokeratin (CK), CD45, PD-L1 and a cell cycle dye. The stained samples were analyzed by a flow cytometer alongside stained control cells. Results: Fifty bladder cancer patient and 15 normal donor urine samples were collected and tested with this assay. We could distinguish epithelial cells (pan-CK+) and white blood cells (WBCs, CD45+) in urine samples and obtain PD-L1 expression and DNA content information simultaneously from these cell populations. The patient samples showed a significantly higher percentage of WBCs with substantial PD-L1 expression (P < 0.001). The percentage of PD-L1 positive epithelial cells was not distinguishable between normal donor and patient samples. However increased post G1 epithelial cells ( > 5%) were observed in a majority of bladder cancer patients, with around 25% of samples showing a DNA index above 1.05. Conclusions: We developed a flow cytometry-based method to investigate PD-L1 and DNA content simultaneously in cells from urine samples that could provide us with a new method to accurately identify bladder cancer patients through urine testing.

Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients

1997 ◽  
Vol 74 (6) ◽  
pp. 625-629 ◽  
Author(s):  
Jürgen F. Linn ◽  
Miriam Lango ◽  
Sarel Halachmi ◽  
Mark P. Schoenberg ◽  
David Sidransky
Keyword(s):  
Bladder Cancer ◽  
Cancer Patients ◽  
Telomerase Activity ◽  
Microsatellite Analysis ◽  
Urine Samples

Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples

Urology ◽  
2005 ◽  
Vol 66 (6) ◽  
pp. 1354-1359 ◽  
Author(s):  
Michal Daniely ◽  
Ronny Rona ◽  
Tal Kaplan ◽  
Shirley Olsfanger ◽  
Lea Elboim ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Cancer Detection ◽  
Urine Samples ◽  
Combined Analysis

Improved urine samples collection for DNA/RNA purification and its application in bladder cancer detection.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e18199-e18199
Author(s):  
Michiko Suwoto ◽  
Paolo Piatti ◽  
Xiaojing Yiang ◽  
Xi Yu Jia ◽  
Yap Ching Chew
Keyword(s):  
Bladder Cancer ◽  
Cancer Detection ◽  
Urine Samples ◽  
Rna Purification

888: Metabolomic Urine Samples Profiling Using High Performance Liquid Chromatography Coupled with Mass Spectrometry to Detect Bladder Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 295-295
Author(s):  
Michael Mullerad ◽  
Haleem J. Issaq ◽  
Alexander Kravtsov ◽  
Timothy Waybright ◽  
Brian Luke ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Bladder Cancer ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
High Performance ◽  
Urine Samples

scholarly journals Diagnostic Value of Telomerase Activity in Patients With Bladder Cancer: A Meta-Analysis of Diagnostic Test

2020 ◽  
Vol 10 ◽  
Author(s):  
Lei Peng ◽  
Jinze Li ◽  
Chunyang Meng ◽  
Jinming Li ◽  
Dandan Tang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Subgroup Analysis ◽  
Meta Analysis ◽  
Negative Likelihood Ratio ◽  
High Specificity ◽  
Diagnostic Value ◽  
Telomerase Activity ◽  
Low Grade ◽  
Potential Biomarker ◽  
Significant Difference

BackgroundThis study aimed to evaluate the diagnostic value of telomerase activity (TA) for bladder cancer (BC) by meta-analysis.MethodsWe conducted a systematic search of studies published on PubMed, Embase, and Web of Science up to June 1, 2019. We used Stata 15 and Review Manager 5.3 for calculations and statistical analysis.ResultsTo evaluate the diagnostic value of TA for BC, we performed a meta-analysis on 22 studies, with a total of 2,867 individuals, including sensitivity, specificity, positive and negative likelihood ratio (PLR, NLR), diagnostic odds ratio (DOR), and 95% confidence intervals (CIs). The pooled parameters were calculated from all studies, and we found a sensitivity of 0.79 (95% CI: 0.72–0.84), a specificity of 0.91 (95% CI: 0.87–0.94), a PLR of 8.91 (95% CI: 5.91–13.43), an NLR of 0.24 (95% CI: 0.15–0.37), a DOR of 37.90 (95% CI: 23.32–61.59), and an AUC of 0.92 (95% CI: 0.90–0.94). We also conducted a subgroup analysis based on the different stages and grades of BC. Results from the subgroup analysis showed that there was no significant difference in TA in either high and low stages of BC, but that low-grade tumors had a lower TA than high-grade tumours.ConclusionsTA can be used as a potential biomarker for the diagnosis of bladder cancer with its high specificity. Rigorous and high-quality prospective studies are required to verify our conclusion.

Sign in / Sign up

Export Citation Format

Share Document